On the upside
Shares of Poniard Pharmaceuticals (Nasdaq: PARD) rebounded after reporting positive trial results for its chemotherapy drug picoplatin in colorectal cancer patients. Yesterday, the company said that picoplatin failed a trial for lung cancer patients.
Tween Brands (NYSE: TWB) reversed year ago losses to post a profit for the third quarter that topped analyst estimates.
Dillard's (NYSE: DDS) swung to a third quarter profit as the company controlled inventory and welcomed a tax benefit.
On the downside
QuickLogic (Nasdaq: QUIK) announced a direct offering of approximately 4.3 million common shares.
InterMune (Nasdaq: ITMN) changed a midstage clinical trial of its experimental hepatitis C treatment citing possible liver damage.
Jacobs Engineering (NYSE: JEC) disappointed with fourth quarter earnings that missed expectations and forecast 2010 results that fell short of estimates.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 4 on both the NYSE and Nasdaq. The Russell 2000 which tracks small cap stocks eased a fraction to 602.
